Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mastocytosis.

Dean D Metcalfe1

  • 1Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Novartis Foundation Symposium
|April 12, 2006
PubMed
Summary
This summary is machine-generated.

Systemic mastocytosis (SM) is a clonal disorder causing symptoms via mediator release and infiltration. Treatment varies by disease category, with targeted therapies guided by c-kit mutation analysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical relevance of mosaic variants detected by exome sequencing.

The Journal of allergy and clinical immunology·2026
Same author

Evidence for dysbiosis in the gut microbiome of patients with systemic mastocytosis.

The journal of allergy and clinical immunology. Global·2026
Same author

Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium.

The Journal of allergy and clinical immunology·2025
Same author

Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis.

British journal of haematology·2025
Same author

Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial.

The journal of allergy and clinical immunology. Global·2025
Same author

Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis.

Frontiers in allergy·2025
Same journal

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Novartis Foundation symposium·2009
Same journal

Translating mucosal antigen based prevention of autoimmune diabetes to human.

Novartis Foundation symposium·2009
Same journal

Re-establishing immune tolerance in type 1 diabetes via regulatory T cells.

Novartis Foundation symposium·2009
Same journal

Immune markers of disease and therapeutic intervention in type 1 diabetes.

Novartis Foundation symposium·2009
Same journal

Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.

Novartis Foundation symposium·2009
Same journal

CD8 and cytotoxic T cells in type 1 diabetes.

Novartis Foundation symposium·2009
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Systemic mast cell disorders are typically clonal, originating from mast cells and their progenitors.
  • Symptoms arise from pathological mediator release and destructive mast cell infiltration.
  • Cutaneous mastocytosis often regresses, particularly in children, while systemic mastocytosis (SM) is persistent.

Purpose of the Study:

  • To outline the classification and clinical course of systemic mastocytosis.
  • To discuss current therapeutic strategies based on disease severity and genetic mutations.
  • To highlight the role of c-kit mutation analysis in guiding targeted therapy.

Main Methods:

  • Classification of mastocytosis into five categories: Indolent SM, aggressive SM, SM with associated clonal haematological non-mast cell-lineage disease (AHNMD), and mast cell leukaemia (MCL).

Related Experiment Videos

  • Review of treatment approaches including symptomatic management, cytoreductive therapy, and targeted kinase inhibitors.
  • Analysis of c-kit mutations, specifically the D816V mutation, and their impact on treatment response.

    • Main Results:

    • A somatic c-kit mutation at codon 816 is frequently detected in hematopoietic cells of SM patients.
    • The D816V mutation is associated with resistance to certain tyrosine kinase inhibitors like imatinib.
    • Imatinib has shown success in specific cases, including SM-hypereosinophilic syndrome (HES) with FIPL1/PDGFRA fusion.

    Conclusions:

    • Mastocytosis management requires a tailored approach based on disease classification and genetic profiling.
    • Targeted therapies, particularly 'Kit-targeting' tyrosine kinase inhibitors, are most effective when guided by c-kit mutational analysis.
    • The role of bone marrow transplantation in mastocytosis treatment is still under investigation.